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Summary Treatment with combined IL-2 and a-IFN has resulted in synergistic antitumour efficacy in animal
studies. The mechanisms responsible for this synergy remain unclear. In this study, several immune parameters
which might be involved in mediating antitumour activity have been monitored serially in 15 patients with
advanced malignant melanoma or renal cell cancer during treatment with concurrent IL-2 and a-IFN. Both
drugs were given subcutaneously in low to moderate (outpatient) dosages but for a prolonged duration. This
treatment resulted in remarkable immunomodulation. In vivo induction of cytotoxicity against K562 and
Daudi target cells was consistently seen, and percentages of peripheral blood cells expressing CD 25 (IL-2
receptor) and CD 56 (Leu-19) increased. In vitro proliferation of lymphocytes in response to IL-2 was
enhanced during the treatment periods, whereas spontaneous proliferation was inhibited. Moreover, correla- tions between immune parameters and subsequent clinical responses were present in the early phase of the
study. Cytotoxicity levels generated in vivo as well as the percentage of CD 56+ lymphocytes were higher in
patients who responded to treatment than in non-responders. In contrast, responders had lower levels of CD 25+ cells. These findings indicate that it might be possible to select patients who are likely to benefit from
prolonged immunotherapy.
Interleukin-2 (IL-2) and interferon-alpha (a-IFN) are cyto-
kines with independent antitumour activities in animal
models as well as in some human malignancies including
malignant melanoma (MM) and renal cell cancer (RCC). The
exact mechanisms by which IL-2 and a-IFN cause tumour
regression in vivo are as yet unknown; from experimental
studies, however, both agents are known to have a number
of functions which possibly contribute to their antitumour
efficacy.
IL-2 has initially been described for its capability to sup-
port the growth of T lymphocytes. In addition, IL-2 plays a
central role in the regulation of cell-mediated non-major
histocompatibility complex (MHC)-restricted cytotoxicity.
IL-2 augments the cytolytic activity of natural killer (NK)
cells (Henney et al., 1981) and induces the generation of
lymphokine-activated killer (LAK) cells (Grimm et al., 1982).
NK cells are lymphocytes exhibiting a spontaneous cytotox-
icity against some tumour cells and tumour cell lines
(Robertson & Ritz, 1990). Incubation of peripheral blood
lymphocytes (PBL) in IL-2 for at least 3 days results in the
generation of LAK cells which are capable of lysing NK
resistant tumour cell lines and fresh tumour cells (Grimm et
al., 1982) but show only minimal cytotoxicity against normal
cells (Sondel et al., 1986). It has been shown in human and
animal studies that significant LAK activity can also be
generated in vivo by treatment with appropriate IL-2
regimens.
The cell populations mediating NK and LAK cytotoxicity
are functionally defined and composed of phenotypically
heterogeneous lymphocyte subpopulations. The surface anti-
gen Leu-19 (CD 56) is expressed by virtually all human NK
effectors (Lanier et al., 1986) although they are hetero-
geneous for the expression of additional markers; moreover,
less than 5% of T lymphocytes, monocytes, and neutrophils
are Leu-l9+ (Robertson & Ritz, 1990). Leu-19 is therefore
used most extensively as NK cell marker. In addition, Leu-19
expression has been demonstrated in the majority of LAK
effectors, and there is considerable evidence that LAK
activity is largely mediated by IL-2 activated NK cells
(Ortaldo et al., 1986; Phillips & Lanier, 1986; Weil-Hillman
et al., 1989).
IL-2 also stimulates proliferation of various lymphocyte
subpopulations (Bich-Thuy et al., 1986) including NK cells
(Trinchieri et al., 1984; Yamada et al., 1987). After in vivo
administration of IL-2, considerable changes in the pheno- typic composition of circulating lymphocytes are usually
observed, including increased percentages of cells expressing
the IL-2 receptor (CD 25) and Leu-19 (Ellis et al., 1988;
Lotze et al., 1987).
a-IFN is known to augment the cytotoxic activity of NK
cells (Herberman et al., 1982). Moreover, a-IFN has direct
antiproliferative effects on normal and neoplastic cells (Czar-
niecki et al., 1984; Fidler et al., 1987). In tumour cells, a-IFN
enhances the expression of cell surface molecules including
tumour-associated antigens and class I MHC antigens
(Giacomini et al., 1984; Weber & Rosenberg, 1988) and is
capable of promoting a partial reversal of the malignant
phenotype (Hicks et al., 1981).
In animal studies, the administration of combined IL-2
and x-IFN resulted in synergistic antitumour efficacy
(Brunda et al., 1987; Cameron et al., 1988; Iigo et al., 1989;
Kim et al., 1989; Rosenberg et al., 1988). The mechanisms
responsible for this in vivo synergy remain largely speculative,
although the interactions between IL-2 and x-IFN have been
investigated in a number of in vitro studies. These experi-
mental data clearly show that combination of a-IFN and
IL-2 results in a more than additive augmentation of NK
activity (Brunda & Davatelis, 1985). In contrast, in vitro
generation of LAK cells seems to be modulated by a-IFN in
a complex manner. Culture of PBL in IL-2 and a-IFN may
result in either enhanced or impaired LAK activity depending
on experimental conditions such as timing ofa-IFN addition,
sequential or concurrent exposure of PBL to IL-2 and m-IFN,
a-IFN concentration, and duration of the culture period
(Brunda et al., 1986; Chikkala et al., 1990; Di Raimondo et
al., 1987; Sone et al., 1988; Tokuda et al., 1989). In addition, a-IFN may also affect tumour cells resulting in either in-
creased or reduced susceptibility to NK and LAK cell lysis
depending on the experimental conditions and the target cells
used (Di Raimondo et al., 1987; Greenberg et al., 1984;
Metha et al., 1991; Trinchieri et al., 1981).
In contrast to an abundance of in vitro studies, only
limited data exist on immunological effects of combined IL-2
and a-IFN occurring in vivo. In the present study, we have
serially monitored in vivo generated cytotoxicity against K562
and Daudi target cells, lymphocyte proliferation, and expres-
sion of selected lymphocyte surface markers in cancer
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patients undergoing treatment with combined IL-2 and a-
IFN. Whilst detailed clinical data of this study will be pre-
sented elsewhere, we report here on the immunological
aspects.
Material and methods
Patients and treatment
The immunological data analysed in this paper were gener-
ated by 15 patients entered into a phase II trial. All patients
had advanced, progressing MM or RCC. Treatment con-
sisted of concurrent interleukin-2 (IL-2, Proleukin®D; kindly
provided by EuroCetus Ltd.*), and interferon-alpha-2a (a-
IFN, RoferonO-A; Hoffmann-LaRoche). Both drugs were
administered subcutaneously on an outpatient basis. IL-2
was given five times a week (Monday to Friday) in fixed
single doses of 18 x 106 IU, and a-IFN was given three times
a week (Monday, Wednesday, Friday) in fixed single doses of
3 x 106IU, for three successive weeks, followed by a rest
period of 2 weeks (Figure 1). In case of tumour remission or
stable disease, treatment was continued to a maximum of
four cycles with unchanged drug dosages. All patients
included in this analysis received at least one full treatment
cycle and were evaluable for clinical response. Complete or
partial remissions (CR/PR) were seen in three patients, no
change (NC) of tumour parameters in four patients, and
progressive disease (PD) in eight patients. All three respon-
ders had MM.
Patient monitoring and samplepreparation
Thirty to forty ml of heparinised blood were drawn from
patients on days 1 (pretreatment), 5, 12 and 19 of each
treatment cycle (sampling days; see Figure 1) for serial assess-
ments of cytotoxicity, surface marker analysis, and prolifera-
tion assays. PBL were separated by Ficoll-Hypaque density
gradient centrifugation and resuspended in RPMI 1640 tissue
culture medium supplemented with L-glutamine (2.0 mM),
ampicillin (200 mg 1'), streptomycine (250 mg I') and 10%
(v/v) heat-inactivated foetal calf serum (subsequently referred
to as 'medium'). Viable cells were then counted by the trypan
blue exclusion method. Excess cells were cryopreserved by
controlled rate freezing in 10% dimethylsulfoxide and stored
in liquid nitrogen.
Cytotoxicity assay
A 4 h 5"Cr-release assay was applied to test cytotoxic
activities, using fresh PBL as effector cells and the two
tumour cell lines K562 and Daudi as target cells. Details of
the technique have been described previously (Ghosh et al.,
1989). Briefly, targets were labelled with 0.1 mCi 51Cr/106
cells for 1 h at 37°C, washed twice, and then incubated for
30 min at 37°C with medium to reduce spontaneous chrom-
ium release. After two further washings, the targets were
resuspended in medium for a concentration of 5 x 104 cells
ml-'. One hundred iLl of effector cells in appropriate dilu-
tions and an equal volume of labelled targets were added to
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LP2 tubes resulting in effector:target (E:T) ratios of 100:1,
40:1, 20:1 and 10:1. Maximum chromium release was
obtained by additing 100 ll of 1% Tween 20 detergent to the
targets instead of effectors, and spontaneous release by add-
ing 100 g1 of medium. After short centrifugation (600 r.p.m.,
5 min), the LP2 tubes were incubated for 4 h (37°C, 5%
C02). All assays were done in triplicate, and no IL-2 was
present during the incubation period.
Following incubation, 100 lI of supernatant were removed
to LP3 tubes, and the radioactivity of supernatant and
remaining pellet was counted in a gamma counter. Cytotox-
icity results are expressed as percentage specific cytotoxicity,
which was calculated according to the formula
% cytotoxicity = 100 x experimental c.p.m. - spontaneous c.p.m. maximum c.p.m. - spontaneous c.p.m.
Statistical analysis was done for serial cytotoxicity results, as
assessed on the four sampling days per treatment cycle, as
well as for peak cytotoxic activity which was defined as
maximum cytotoxicity reached at any occasion during one
treatment cycle.
Lymphocytes phenotype analysis
In nine patients (2 CR/PR, 1 NC, 6 PD) enough PBL were
left for serial analysis of two surface markers during the first
treatment cycle. This was performed by an indirect immuno-
fluorescence method on cryopreserved and thawed cells.
Monoclonal antibodies used were DAKO-IL2-R (Dakopatts,
Denmark), directed against the 55 kDa polypeptide chain of
the IL-2 receptor (CD 25, Tac antigen); and Leu-19 (Becton
Dickinson), directed against the NK cell marker CD 56
(NKH1). A FITC-conjugated rabbit anti-mouse immunoglo-
bulin antibody (Dakopatts, Denmark) was used as second
step reagent, and the percentage of fluorescence positive cells
was assessed by FACS analysis. Results obtained serially on
the sampling days as well as peak percentages, which were
defined as highest relative numbers of fluorescence positive
cells at any occasion during one treatment cycle, were subject
to statistical analysis.
PBLproliferation assay
Spontaneous (unstimulated) and stimulated proliferation of
PBL was serially tested, the former by culture of cells in
medium alone, the latter by incubation in phytohemagglut-
inin (PHA; Wellcome) or IL-2. Fresh PBL were seeded in
96-well U-bottomed microtiter plates under sterile conditions.
Each well contained 2 x 105 cells in 200 ,lI ofmedium with or
without the stimulant. PHA was added for final concentra-
tions of 1.0fg ml-', 0.1 fgml', or 0.01 fgml-', and IL-2
was added for final concentrations of 1,200 IU ml-', 240 IU
ml-', or 120 IU ml-'. All tests were done in triplicate. Cul-
tures were incubated for 96 h at 37°C in a humidified atmo-
sphere containing 5% CO2. For the last 4 h, each well was
pulsed with 1 ltCi 3H-thymidine. Cultures were harvested
semiautomatically onto fibreglass filters, and filters were
dried overnight at room temperature. Radioactivity was
counted by liquid scintillation. Results for spontaneous pro-
liferation are given as counts per min (c.p.m.), and results for
stimulated proliferation are expressed as a stimulation index
(SI) in order to take account of fluctuations in spontaneous
proliferation. The SI was computed as follows:
SI = c.p.m. (stimulated)
c.p.m. (spontaneous)
I I I I I
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Figure 1 Treatment plan and collection of blood samples.
Peak proliteration was defined as maximum proliferation
(c.p.m. or SI) reached at any occasion during one treatment
cycle.
Statistical analysis
Statistical analysis was done by non-parametric tests. The
Wilcoxon matched-pairs signed-ranks test (hereafter referred
Sampling days 1 5
*Specific activity: 18 x 106 international units (IU) per mg of
protein. 1 Cetus unit = 6 IU (all IL-2 dosages are given in
IU).
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to as Wilcoxon test) was used for paired samples. Data from
patients in different response groups were compared by the
Kruskal-Wallis test or the Mann-Whitney test as appropriate.
All P-values reported are 2-tailed, and P<0.05 was con-
sidered to indicate statistical significance.
Results
In vivo cytotoxicity
Pretreatment cytotoxicity Median pretreatment cytotoxic
activities against both K562 and Daudi targets are given in
Tables I and II for each of the 4 E:T ratios tested. An
activity of > 10% against the K562 target was observed in
79% of patients before treatment. One patient (who subse-
quently responded to therapy) had an unusual high pretreat-
ment anti-K562 activity of 74% for the E:T ratio of 100:1,
and values up to 46% were found in the remaining patients.
A maximum pretreatment cytotoxicity of 13% against the
Daudi target was seen for the same E:T ratio.
Cytotoxicity during the first treatment cycle In vivo induc-
tion ofcytotoxicity against both K562 and Daudi targets was
consistently seen after initiation of IL-2/a-IFN therapy. At
an E:T ratio of 100:1, peak anti-K562 activities obtained by
individual patients ranged from 28% to 74% (median 50%).
Individual peak activities against Daudi targets ranged from
7% to 58% (median 35%), with only one patient not exceed-
ing the 20% limit. The differences between pretreatment and
peak activity were statistically significant for both targets at
each of the four E:T ratios tested (see Tables I and II).
Figures 2a and 2b show that cytotoxicity was markedly
augmented by day 5, the increase since day 1 being statis-
tically significant for both anti-K562 and anti-Daudi
activities (P<0.013 for the K562 target, and P<0.009 for
the Daudi target, at each of the four E:T ratios; Wilcoxon
test). A continuing increase of cytotoxicity levels was seen
during the second treatment week before a plateau phase was
reached during the third week.
Relationship between cytotoxicity and response Cytotoxicity
results were compared between patients grouped according to
Table I Pretreatment and peak cytotoxicity against K562 targets, assessed during the first
treatment cycle for four E:T ratios. Data represents medians (and range) of % cytotoxicity
Cytotoxicity against K562 targets
100:1 40:1 20:1 10:1
Pretreatment cycle 1: all pat. 18.9 15.8 10.8 6.0
(4.5-74.0) (3.9-71.4) (0.0-56.3) (0.0-46.8)
Peak cycle 1: all pat. 50.0 40.4 26.7 18.5
(28.0-74.0) (15.4-71.4) (9.6-56.3) (7.6-52.3)
P (Wilcoxon test)a 0.002 0.002 0.002 0.002
Pretreatment cycle 1: CR/PR 35.9 25.6 18.4 9.4
(9.0-74.0) (5.3-71.4) (8.2-56.3) (5.3-46.8)
NC 21.4 16.1 13.3 9.1
(12.3-38.4) (12.3-30.8) (8.1 -20.9) (3.0- 14.7)
PD 16.6 10.9 5.8 5.9
(4.5-45.5) (3.9-45.5) (0.0-33.7) (0.0-23.5)
P (Kruskal-Wallis test)b n.s. n.s. n.s. n.s.
Peak cycle 1: CR/PR 58.8 48.5 36.3 27.9
(43.0-74.0) (27.4-71.4) (19.4-56.3) (10.2-52.3)
NC 40.8 33.3 22.6 16.5
(26.4-73.9) (20.8-69.0) (16.7-41.8) (13.9-32.3)
PD 50.9 40.0 25.2 19.7
(33.7-64.4) (15.4-64.4) (9.6-50.2) (7.6-32.2)
P (Kruskal-Wallis test)' n.s. n.s. n.s. n.s.
aPretreatment vs peak. "CR/PR vs NC vs PD. n.s. = not significant.
Table II Pretreatment and peak cytotoxicity against Daudi targets, assessed during the first
treatment cycle for four E:T ratios. Data represents medians (and range) of % cytotoxicity
Cytotoxicity against Daudi targets
100:1 40:1 20:1 10:1
Pretreatment cycle 1: all pat. 5.8 6.2 4.9 1.1
(0.0-12.7) (0.0-8.0) (0.0-8.6) (0.0-6.3)
Peak cycle 1: all pat. 34.8 30.0 21.2 15.0
(7.4-57.7) (7.1-56.8) (7.3-35.7) (2.3-27.5)
P (Wilcoxon test)a 0.001 0.002 0.001 0.001
Pretreatment cycle 1: CR/PR 12.3 6.9 5.8 0.4
(9.4-12.7) (5.2-8.0) (4.9-6.0) (0.0-5.1)
NC 6.8 6.6 5.3 2.5
(1.9-11.1) (5.9-6.7) (2.8-8.6) (0.3-5.1)
PD 2.8 2.8 2.6 1.1
(0.0-10.8) (0.0-7.5) (0.0-8.3) (0.0-6.3)
P (Kruskal-Wallis test)b 0.036 n.s. n.s. n.s.
P (Mann-Whitney test)c 0.030 n.s. n.s. n.s.
Peak cycle 1: CR/PR 57.7 44.0 25.4 26.9
(49.0-57.7) (32.9-56.8) (19.7-35.7) (16.5-27.1)
NC 33.3 24.9 20.7 14.8
(21.6-42.6) (16.2-30.0) (7.8-21.4) (2.3-16.5)
PD 31.7 27.2 21.4 13.5
(7.4-52.6) (7.1-48.7) (7.3-32.2) (6.1-27.5)
P (Kruskal-Wallis test)" 0.049 n.s. n.s. n.s.
P (Mann-Whitney test)c 0.025 n.s. n.s. n.s.
aPretreatment vs peak. bCR/PR vs NC vs PD. CCR/PR vs PD. n.s. = not significant.166 A. VON ROHR et al.
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Figure 3 Cytotoxicity against K562 targets for patients with
partial or complete response (PR/CR), no change (NC) of
tumour parameters, and progressive disease (PD). Data points
represent median cytotoxicity at an effector:target ratio of I00: 1.
Shaded areas = treatment periods (4 cycles).
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Figure 2 a and b, Cytotoxicity against K562 targets (top) and
against Daudi targets (bottom) during the first treatment cycle as
assessed with four different E:T ratios. Data points represent
median cytotoxicity for all patients. Shaded area = treatment
period. -0- 100:1; -0- 40:1; -A- 20:1; -*- 10:1.
their clinical response to therapy, i.e. PR/CR vs NC vs PD.
With both targets, median pretreatment as well as peak
activities during the first cycle were greater in patients who
subsequently achieved a PR/CR than in non-responders
(Figures 3 and 4, Tables I and 11). The differences between
patient groups were statistically significant for the anti-Daudi
activity at the E:T ratio of I00: I but not at the lower ratios,
and neither for the anti-K562 activity (Tables I and II).
During the rest period after the first treatment course, re-
sponders were able to maintain higher cytotoxicity levels
than non-responders.
Cytotoxicity duringsubsequent treatment cycles During the
second treatment cycle, cytotoxicity levels were again related
to the clinical response (Figures 3 and 4). Patients subse-
quently achieving a PR/CR generated higher activities
against both targets than those with NC, and no significant
augmentation of cytotoxicity was seen in patients with PD.
No patient with PD received more than two treatment
courses. Patients with NC were not able to maintain their
cytotoxicity levels after the second course, in contrast to
responders who preserved their high levels during periods
without therapy.
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Figure 4 Cytotoxicity against Daudi targets for patients with
partial or complete response (PR/CR), no change (NC) of
tumour parameters, and progressive disease (PD). Data points
represent median cytotoxicity at an effector:target ratio of I00:1.
Shaded areas = treatment periods (4 cycles).
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Surface markers: Leu-19 (CD 56)
Leu-19 expression during thefirst treatment cycle The med-
ian percentages ofperipheral blood Leu-19' cells as assessed
by serial measurements before and during the first treatment
cycle are depicted in Figure 5. In pretreatment samples, PBL
positive for Leu-19 ranged from 4% to 20% (median 6%).
Leu-19 expression increased continuously during treatment
for a maximum on day 19 (median 24%, range 13-30%). As
compared to day I (pretreatment), the relative number of
Leu-19' cells was significantly augmented on days 12 and 19
(P<0.05, Wilcoxon test).
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Figure 5 Peripheral blood cells with positive staining for Leu-19
(CD 56) and IL-2 receptor (CD 25) during the first treatment
cycle. Data points represent medians for 9 patients. Shaded
area = treatment period.
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Relationship between Leu-19+ PBL and response In pretreat-
ment samples, no statistically significant differences in the
percentage of Leu-19+ cells were found between responding
vs non-responding patients (data not shown). During the first
treatment cycle, peak percentages of Leu-19+ PBL in individ-
ual patients ranged from 15% to 32% (see Table III). The
respective medians were 24% for all patients, 30% for
patients achieving a CR/PR, and 20% for patients with PD.
This difference between responders and non-responders
reached statistical borderline significance (Table III).
Surface markers: IL-2 receptor (CD 25, Tac)
IL-2 receptor expression during thefirst treatment cycle The
proportion of CD 25+ peripheral blood cells was small in
pretreatment samples (median 3%, range 1- 13%). It can be
seen from Figure 5 that this percentage increased during the
first treatment cycle until day 12 (median 11%, range
5-28%), followed by a plateau phase through to day 19.
Statistically significant increases since day 1 (pretreatment)
were present on days 12 and 19 (P<0.05, Wilcoxon test).
Relationship between IL-2 receptor expression and response
In pretreatment samples, relative numbers of CD 25+ peri-
pheral blood cells were not significantly different between
response groups (data not shown). During the first treatment
course, individual patients achieved peak percentages of CD
25+ cells ranging from 5% to 28%, with medians of 12% for
all patients, 9% for patients with subsequent CR/PR, and
14% for patients with PD, respectively (see Table III). This
association between clinical remission and lower levels of CD
25+ cells was not statistically significant.
Proliferation assay
Spontaneous proliferation of PBL during in vivo treatment
with IL-2/ai-IFN A certain variability in spontaneous PBL
proliferation was present between individual patients. Never-
theless, a uniform treatment-related proliferation pattern was
observed during the four therapy cycles. Figure 6 shows that
the in vivo therapy always resulted in a temporary decrease of
3H-thymidine uptake, although this effect was minimal dur-
ing the fourth cycle. Spontaneous proliferation recovered
either later during treatment or during the treatment free
interval. No significant correlation between clinical response
and spontaneous proliferation was present (data not shown).
In vitro stimulation ofPBL with PHA Before initiation of in
vivo therapy, PHA at the two higher test concentrations
induced proliferation of patients' PBL, whereas the lowest
concentration (0.01 ;lgml-') hardly had any effect. This is
illustrated by median pretreatment SI of 88, 19, and 1.1,
respectively. During in vivo therapy, the ability of PBL to
proliferate in response to PHA showed no reproducible treat-
ment-related pattern (see Figures 7a-c). SI showed high
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Figure 6 Spontaneous PBL proliferation (in medium alone).
Data points represent medians of c.p.m. for all patients. Shaded
areas = treatment periods (4 cycles).
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Figure 7 a-c, PBL proliferation after in vitro stimulation with
PHA in three different concentrations for 96 h. Data points
represent medians of SI for all patients. Shaded areas = treatment
periods (4 cycles).
Table III Pretreatment and peak percentage ofPBL positive for Leu-19 (CD
56) and IL-2 receptor (CD 25) during the first treatment cycle. Data represent
medians (and range) for nine patients
Leu-19 IL-2 receptor
Pretreatment cycle 1: all pat. (n = 9) 6.45 3.2
(3.6-19.7) (0.9-13.2)
Peak cycle 1: all pat. (n = 9) 24.1 11.7
(15.1-32.2) (5.4-28.3)
P (Wilcoxon test)a 0.008 0.008
Peak cycle 1: CR/PR (n = 2) 30.0 9.0
(27.9-32.2) (8.9-9.0)
NC(n=1) 27.0 13.2
PD (n= 6) 20.2 14.3
(15.1-24.7) (5.4-28.3)
P (Kruskal-Wallis test)b 0.061 n.s.
P (Mann-Whitney test)c 0.046 n.s.
aPretreatment vs peak. bPeak cycle 1, CR/PR vs NC vs PD. cPeak cycle 1,
CR/PR vs PD. n.s. = not significant.
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Figure 8 PBL proliferation after in vitro stimulation with IL-2 in
three different concentrations for 96 h. Data points represent
medians of SI for all patients. Shaded areas = treatment periods
(4 cycles).
interindividual (on a given sampling day) and intraindividual
(during the whole study duration) variabilities. Proliferation
of PBL in response to PHA was not associated with clinical
response (data not shown).
In vitro stimulation of PBL with IL-2 In pretreatment sam-
ples, IL-2 was capable of inducing PBL proliferation in a
dose-dependent manner. Median SI for the three IL-2 con-
centrations tested were 11, 5, and 4, respectively (see Table
IV). Proliferative responses of PBL to IL-2 temporarily in-
creased during each treatment cycle (see Figure 8). The
results for the first cycle are given in Table IV, and it can be
seen that the differences beween pretreatment and peak SI
were highly significant (P<0.005 for each of the IL-2 con-
centrations, Wilcoxon test). Proliferative response of PBL to
IL-2 was not associated with clinical responses (data not
shown).
Discussion
The present study demonstrates that concurrent administra-
tion of IL-2 and a-IFN to patients with advanced malig-
nancy is biologically active. Our treatment regimen resulted
in remarakable immunomodulation, most notably in vivo
activation of PBL with induction of cytotoxicity against the
two targets K562 and Daudi. K562 cells are very sensitive to
NK cytolysis but may also be killed by LAK cells (Ortaldo &
Longo, 1988). In contrast, Daudi cells are LAK-susceptible
but relatively NK-resistant targets. It may therefore be con-
cluded that the cytotoxicity induced by IL2/a-IFN treatment
is largely due to in vivo generation of LAK activity. Aug-
mented cytotoxicity levels were usually seen after the first five
treatment days, but both anti-K562 and anti-Daudi activity
continued to increase thereafter, and patients were capable of
maintaining elevated cytotoxicity levels throughout the treat-
ment period.
Moreover, levels of anti-K562 and anti-Daudi activity were
found to be higher in patients who subsequently responded
Table IV Pretreatment and peakstimulation index (SI)during thefirst
treatment cycle for stimulation of PBL with IL-2 in three concentra-
tions. Data represent medians (and range) of SI for all patients
IL-2
1200 IUml-' 240 IUml-' 120 IUml-'
Pretreatment cycle 1: 10.6 5.1 4.0
(4.5-44.7) (2.4-16.9) (2.0-13.2)
Peak cycle 1: 39.6 17.3 10.6
(8.9-90.9) (4.9-64.7) (3.9-60.6)
P (Wilcoxon test)a 0.005 0.003 0.005
aPretreatment vs peak.
to treatment than in non-responders. This correlation with
subsequent clinical outcome was seen in the early phase and
even before initiation of treatment, and it reached statistical
significance for pretreatment anti-Daudi activity and peak
activity against the same target during the first treatment
cycle. However, differences between response groups became
even more evident during and after the second treatment
cycle. Responders were not only capable ofgenerating higher
cytotoxicity levels during treatment periods but also of main-
taining higher levels during treatment free intervals. These
results support preclinical data which indicate that generation
of cytotoxic immune effector cells, particularly LAK cells, is
a crucial step in achieving tumour regression by IL-2-based
immunotherapy (Mule et al., 1986).
Although the number of published therapeutic trials using
combined IL-2 and a-IFN is increasing, only few data are
reported on monitoring of in vivo cytotoxicity. In vivo induc-
tion of cytotoxic activity against NK- and LAK-sensitive
targets, but no consistent relationship between antitumour
effect and extent of cytotoxicity, has been observed in a
phase I trial (Budd et al., 1989). Others (Pichert et al., 1991)
have investigated the inducible cytotoxicity (with additional
in vitro stimulation of patients' PBL by IL-2 after IL-2/a-
IFN treatment) which must not be mistaken for in vivo
cytotoxicity (Lamers et al., 1991). In one clinical trial, IL-2
has been used in combination with interferon-beta which, like
a-IFN, is a type I interferon. Analysis of in vivo cytotoxicity
in this study demonstrated a remarkable similarity to our
data in so far as maximum killing of NK- and LAK-sensitive
target cells was higher in responders than in non-responding
patients, the difference being statistically significant for the
activity against LAK-sensitive targets (Krigel et al., 1990).
,In contrast, in vivo generation of cytotoxicity has been
monitored in a number of therapeutic studies using IL-2
alone (Creekmore et al., 1989; Gambacorti-Passerini et al.,
1988; Ghosh et al., 1989; Klasa et al., 1990; McMannis et al.,
1988; Paciucci et al., 1989; Rosenthal et al., 1988; Sondel et
al., 1988; Sosman et al., 1988). Treatment-induced augmenta-
tion of activity against NK-sensitive targets was a common
observation. In contrast, in vivo generation of LAK activity
was not seen consistently. It appears from these studies that
optimum in vivo LAK cell generation requires an IL-2 treat-
ment for at least four consecutive days, corresponding to the
in vitro LAK cell generation which requires a minimum
duration of 3 days for culture of PBL in IL-2. Moreover, the
schedule and route of IL-2 administration is an additional
critical factor in obtaining optimum LAK cell activity. For
instance, it has become clear that IL-2 given as a continuous
intravenous (i.v.) infusion has greater biological effects than
the same total dose given as bolus i.v. injection(s) (Kohler et
al., 1989; Thompson et al., 1989). In order to get best in vivo
induction of LAK activity, prolonged therapeutic IL-2 serum
concentrations may therefore be superior to short though
high peak levels. Pharmacokinetic studies suggest that a sin-
gle IL-2 dose of 18 x 106 IU, as applied in our regimen, given
subcutaneously to a typical human with a body surface area
of 1.7 m2 will result in a serum level ofapproximately 100 IU
ml-' (Konrad et al., 1990). This is only 2% of the level
which is obtained if the same dose is given as an i.v. bolus,
but it is in the same range as the steady state concentration
which is obtained after continuous infusion of the same dose
over 24 h. Moreover, the serum concentration after a sub-
cutaneous injection remains fairly constant for about 8 h,
whereas the serum level after bolus i.v. administration
decreases with a half-life of 12.9min (Konrad et al., 1990).
These data may explain the remarkably high in vivo cytotox-
icity levels seen in our study although low to moderate
(outpatient) drug dosages have been used. However, our
study design was not suitable to assess the relative contribu-
tion of a-IFN to the process of cytotoxicity generation.
Most therapeutic studies using IL-2 alone, including one
performed in our own institution (Ghosh et al., 1989), failed
to detect any significant differences in in vivo cytotoxicity
between responding and non-responding patients. A few
trials, however, reported on higher cytotoxicity levels inIL-2 PLUS a-IFN THERAPY 169
patients with clinical response (Klasa et al., 1990; Paciucci et
al., 1989; Yasumoto et al., 1987). The variability in these
findings suggests that many factors related both to the treat-
ment and to the cytotoxicity assay (frequency and timing of
assays, expression of cytolytic activity as percentage cytotox-
icity or as lytic units, target cells and E:T ratios used) may
be crucial for detection of a significant correlation between
cytotoxicity levels and clinical outcome.
Leu-19 is a surface marker which is expressed by a minor-
ity of normal PBL, and Leu-19+ cells typically mediate NK
cytotoxicity (Lanier et al., 1986). There is some evidence that
LAK cells generated in vivo are largely confined to the Leu-
19+ cell population although they are heterogeneous for
co-expression of additional markers (Ellis et al., 1988;
McMannis et al., 1988; Weil-Hillman et al., 1989). In the
present study we were able to demonstrate a statistically
significant increase in the relative number of Leu-19+ cells
during IL-2/a-IFN treatment. This result is in agreement with
findings in other clinical studies using IL-2 in combination
with a-IFN (Budd et al., 1990; Pichert et al., 1991; Zinzani et
al., 1990) or alone (Creekmore et al., 1989; Klasa et al., 1990;
Sosman et al., 1988). The proportion of Leu-19+ cells in-
creased throughout the first treatment cyclie, the peak
percengage being reached at the end of the 3 week treatment
period. A continuing expansion of Leu-19+ lymphocytes dur-
ing the whole treatment period was also observed in a study
where patients were treated with IL-2 alone for 4 weeks
(Sosman et al., 1988).
The CD 25 molecule (Tac antigen), which is expressed by
activated lymphocytes and monocytes, is known to function
as low affinity receptor for IL-2. There is clear evidence from
in vitro studies that the proportion of CD 25+ cells increases
after incubation of PBL with IL-2, but this process is parti-
ally inhibited when additional a-IFN is present in the cul-
tures (Di Raimondo et al., 1987; Sone et al., 1988; Tokuda et
al., 1989). Increased percentages of CD 25+ lymphocytes
have also been observed after in vivo treatment with IL-2 for
several consecutive days (Gambacorti-Passerini et al., 1988;
Ghosh et al., 1989; Klasa et al., 1990; Sondel et al., 1988;
Sosman et al., 1988) whilst regimens using a single weekly
IL-2 dose had little if any effect (Atkins et al., 1986; Creek-
more et al., 1989; Thompson et al., 1987). In our study the
relative number of CD 25+ peripheral lymphocytes was
found to increase significantly after initiation of treatment for
a peak on day 12, followed by a plateau phase through to
day 19, thus indicating that maximum cell activation was
achieved after the second treatment week. The similar kine-
tics of CD 25+ expression and cytotoxic activity during the
first treatment cycle is noteworthy.
Interestingly the phenotype analysis in our study revealed
that peak percentages of Leu-19+ PBL were higher in respond-
ing patients than in patients with progressing disease. In
contrast, peak percentages of CD 25+ cells were lower in
responders than in non-responders. These results are remark-
ably consistent with data recently reported by another group
(Kirchner et al., 1990; Lopez Hanninen et al., 1991). In their
study, the same correlations between clinical response and
expression of Leu-19 and CD 25 by peripheral blood cells
were observed in cancer patients who were, as in our study,
treated with concomitant subcutaneous IL-2 and a-IFN for a
prolonged period.
A prominent effect of IL-2 is the induction of PBL pro-
liferation (Bich-Thuy et al., 1986). In contrast, a-IFN has
antiproliferative properties, and proliferation of human PBL
(as well as murine spleen cells) is inhibited after co-incu-
bation with IL-2 and a-IFN as compared to culture in IL-2
alone (Brunda et al., 1986; Di Raimondo et al., 1987; Sone et
al., 1988; Tokuda et al., 1989). In our study, patients' PBL
obtained repeatedly during in vivo treatment were tested for
their ability to proliferate in vitro by incubation in medium
alone, i.e. without further in vitro drug exposure. This spon-
taneous PBL proliferation was clearly inhibited by the in vivo
treatment, a result which is in agreement with the in vitro
data mentioned. In contrast, augmented spontaneous PBL
proliferation was observed after in vivo treatment with IL-2
alone (Gambacorti-Passerini et al., 1988). It is therefore most
likely that the inhibition of PBL proliferation in our study
was due to the antiproliferative effect of x-IFN. This con-
clusion is supported by the observation that spontaneous
PBL proliferation recovered during the treatment free inter-
vals.
There is some evidence that generation of LAK cytotox-
icity results from a functional activation rather than from a
proliferative expansion of LAK precursors (Blay et al., 1989;
Ramsdell et al., 1988). Moreover, kinetic studies revealed
that IL-2 induced enhancement of NK cytotoxicity in PBL
preceded any proliferation (Trinchieri et al., 1984). Therefore
induction of cytotoxic activity and lymphocyte proliferation
seem to be two largely independent processes following IL-2
exposure which do not necessarily need to be concordant,
and the relatively high cytotoxicity levels observed in our
study are not in contradiction to the inhibition of PBL
proliferation.
We have also serially examined the proliferative responses
of patients' PBL to in vitro stimulation with IL-2 and PHA.
Augmented PBL proliferation in the presence of IL-2 in vitro
was consistently seen during all four in vivo treatment cycles.
This finding indicates that the in vivo treatment resulted in
activation of a PBL subpopulation which was capable of
responding with more rapid kinetics to IL-2 in vitro. Similar
results were seen in patients who have been treated with IL-2
alone over several consecutive days (Rosenthal et al., 1988;
Sosman et al., 1988). In contrast, PBL proliferation in re-
sponse to PHA, a T cell mitogen, did not appear to change
reproducibly during treatment, and the variability between
individual patients was high. Comparable observations were
reported when patients' PBL were stimulated with PHA in
vitro after in vivo treatment with IL-2 alone (Paciucci et al.,
1989; Rosenthal et al., 1988; Sosman et al., 1988; Thompson
et al., 1987).
In conclusion, remarkable imnmunomodulatory effects were
seen in the present study. Our data have been generated by a
relatively small number of patients and need to be confirmed
in larger patient series. The significant correlation between in
vivo cytotoxicity against Daudi targets and response to
therapy is of special clinical interest, since immune para-
meters correlating with subsequent clinical outcome in the
early phase of immunotherapy might be helpful in selecting
patients who are likely to respond to prolonged treatment.
This issue should be addressed by future studies.
A. von Rohr is in receipt of a fellowship provided by the European
Society for Medical Oncology (ESMO).
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